Lung Cancer Europe

European umbrella organisation for lung cancer advocacy. Connecting organisations to share evidence, strengthen action & push for better care, support & access.

[Lung Cancer Europe @LungCancerEu]

The World Health Organization has published its Global Status Report on Cancer 2026, and #lungcancer remains the leading cause of cancer death worldwide.

Read our 9 takeaways for the lung cancer community, covering screening, late diagnosis, access and prevention: https://t.co/kRL9Sq7TLt #LCSM

[Lung Cancer Europe @LungCancerEu]

Why isn’t CAR T therapy used for #lungcancer?

New research published in Nature Cancer identifies GPNMB as a promising target for CAR T therapy, tackling one of the biggest challenges in developing these treatments for solid tumours.

🔗 https://t.co/GCAfQcdkni #LCSM

[Lung Cancer Europe @LungCancerEu]

Who gets #lungcancer? A 🆕 study of 5,131 people with NSCLC found that, among those diagnosed, women were around 2.5 times more likely than men to have never smoked.

It also found that the proportion of people diagnosed who had never smoked increased from 12.3% in 2005 to 18.0% in 2024.

What could these findings could mean & are they part of a wider shift in how researchers understand who gets lung cancer? #LCSM

🔗 https://t.co/gz0m9JKaBH

[Yago Garitaonaindía @YGaritaonaindia]

🔴 New in @JAMAOnc: Consolidative thoracic RT + atezolizumab maintenance vs atezolizumab alone in ES-#SCLC (TREASURE, phase 2)

• mOS 6.7 vs 13.4 mo (HR 1.55, 95% CI 0.90-2.69)
• mPFS 2.4 vs 2.6 mo → no difference
• SAEs 61% vs 18% | fatal AEs 19% vs 3%

⚠️Same PFS, worse toxicity, no OS gain.

🔍Small & non-confirmatory (halted early), but the message is clear: more is not always better. Selection is needed.

#LCSM #IO

[Nature Cancer @NatureCancer]

🌟Online today

A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages
https://t.co/JG9TwwTWLC

[FlorezLab @Florez_Lab]

🎙️Episode 2 of #MissingConversations in Lung Cancer is now live‼️

@NarjustFlorezMD is joined by Dr Krystle Zuniga and @PauloBergerot to discuss nutrition, exercise & how evidence-based guidance can improve quality of life for lung cancer patients.

🎧- https://t.co/xElDkAXcm3

[Lung Cancer Europe @LungCancerEu]

The World Health Organization has published its Global Status Report on Cancer 2026, and #lungcancer remains the leading cause of cancer death worldwide.

Read our 9 takeaways for the lung cancer community, covering screening, late diagnosis, access and prevention: https://t.co/kRL9Sq7TLt #LCSM

[Kate Sears @MedwatchKate]

Hi friends, it's #LungCancer Wednesday! Here are Top Posts of the Week 🧵

1/ @FordePatrick on divarasib in KRAS G12C NSCLC (Krascendo 1):
https://t.co/f2pOFxsm0k

[AEACaP @AEACaP]

🔵📚Presentación en #Valencia del la guía para cuidadores de pacientes de #cáncerdepulmón

➡️Ofrece información sobre cómo acompañar emocionalmente a lo largo de la enfermedad

🗓️14 de julio
🕔18h
📍Colegio Territorial de Arquitectos. Calle Hernán Cortés, 6

👉 ¡Te esperamos!

[Drew Moghanaki @DrewMoghanaki]

I’ve been saying this out loud all week when reviewing a scan with colleagues. Everyone agrees and hopes they are rewarded in the afterlife!

[Stephen V Liu, MD @StephenVLiu]

Adds to a growing body of evidence - if pts do not need PPIs, they should stop them and judicious use of antibiotics is important for many reasons. These medications have an impact on our microbiome, which is so important to outcomes with immunotherapy.

https://t.co/yV47g9pBJ8

[Lung Cancer Europe @LungCancerEu]

Why isn’t CAR T therapy used for #lungcancer?

New research published in Nature Cancer identifies GPNMB as a promising target for CAR T therapy, tackling one of the biggest challenges in developing these treatments for solid tumours.

🔗 https://t.co/GCAfQcdkni #LCSM

[Jill Feldman @jillfeldman4]

As we get closer to #WCLC26, let's ensure the meeting centers on what it means to live with and beyond #lungcancer.

We want to highlight the people the science is meant to help, not just the data. The fear, hope, side effects, good days, bad days, uncertainty, milestones, and everything in between.

If you are a patient or caregiver, please share what #LivingWithLungCancer means to you. It can be a word, a sentence, a photo, or a short video.

Use #LivingWithLungCancer and #WCLC26 to bring global voices together, and please tag @lpetrillz and @jillfeldman4 so we don’t miss your post.

#LCSM #LivedExperience #PeopleBehindData

[Narjust Florez, MD, FASCO @NarjustFlorezMD]

One of the most important questions in oncology is not just how we treat cancer, but how we detect it earlier.
Studies like this highlight the power of collaboration, patient participation, and translational research in shaping the future of cancer care.

https://t.co/vC3QMB4Lvz

#CancerResearch #CancerPrevention #PrecisionMedicine

[Eric Topol @EricTopol]

Now that we know the gut microbiome's important modulation of the response to cancer immunotherapy (immune checkpoint blockade, ICB), should we change our approach? @Cell_Metabolism
https://t.co/7RiQdFJiUX

[LARVOL @Larvol]

Top Trending Lung Cancer Oncologists in Q2 2026, curated by @Larvol CLIN ranked by views on oncologists posts on 𝕏.

Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/ct6tMIQHii

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #LungCancer #SCLC #esSCLC #NSCLC #LCSM | @M_Torasawa | @StephenVLiu | @HHorinouchi | @lungoncdoc | @ADesaiMD | @GlopesMd | @UOzkerim | @Tony_Calles | @diegoadiazg | @christinemphmd

[Lung Cancer Europe @LungCancerEu]

Who gets #lungcancer? A 🆕 study of 5,131 people with NSCLC found that, among those diagnosed, women were around 2.5 times more likely than men to have never smoked.

It also found that the proportion of people diagnosed who had never smoked increased from 12.3% in 2005 to 18.0% in 2024.

What could these findings could mean & are they part of a wider shift in how researchers understand who gets lung cancer? #LCSM

🔗 https://t.co/gz0m9JKaBH

[OncoDaily @oncodaily]

Lung Cancer Europe - When You Have Lung Cancer, How You Feel Day to Day is Important Information

@LungCancerEu @pompili_cecilia

https://t.co/1FU9XNIZeA

[Eric Topol @EricTopol]

The memory of our immune system cells is truly incredible
The new @SciImmunology dedicated issue
https://t.co/IfeKSrgZqW
https://t.co/itjtqNCi9Z
https://t.co/4HqZsB7RSN

[Lung Cancer Europe @LungCancerEu]

The future of #lungcancer treatment might start in the gut.

The microbes living in the gut, lungs & mouth help steer the immune system. A growing body of research suggests their balance may influence how lung cancer develops, progresses & responds to treatment.

Some bacteria seem to help the body fight cancer. Others may get in the way. Early science, but it points to a genuinely new direction.

https://t.co/c6tyHVKsq0

#LCSM